MEDICINES CO /DE
MDCO evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Lead Asset:
- inclisiran (Phase 3)
What it means
What to watch
Prepared research question
What matters most for MDCO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 2 pipeline candidates · 3 clinical trials for MEDICINES CO /DE.
Run MEDICINES CO /DE through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MEDICINES CO /DE facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is MEDICINES CO /DE's lead drug candidate?
MEDICINES CO /DE's most advanced tracked candidate is inclisiran (Phase 3) for hypercholesterolemia, ASCVD, ASCVD-risk equivalents, familial hypercholesterolemia (FH), homozygous familial hypercholesterolemia (HoFH).
Who is the CEO of MEDICINES CO /DE?
The Medicines Company is the chief executive officer of MEDICINES CO /DE (MDCO).
What therapeutic areas does MEDICINES CO /DE focus on?
MEDICINES CO /DE develops therapies across Oncology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.